Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosrolapitant/palonosetron - Fujian Shengdi Pharmaceutical

Next Previous
Drug Profile

Fosrolapitant/palonosetron - Fujian Shengdi Pharmaceutical

Alternative Names: Fosrolapitant/palonosetron hydrocholoride; HR-20013; Palonosetron/fosrolapitant - Fujian Shengdi Pharmaceutical

Latest Information Update: 17 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fujian Shengdi Pharmaceutical
  • Class Amines; Antiemetics; Aza compounds; Diamines; Esters; Ethers; Fluorinated hydrocarbons; Heterocyclic bicyclo compounds; Isoquinolines; Lactams; Phosphates; Quinuclidines; Spiro compounds
  • Mechanism of Action Neurokinin 1 receptor antagonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 02 Jun 2026 Efficacy and adverse events data from a phase III trial in Chemotherapy induced nausea and vomiting presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
  • 16 Dec 2025 Launched for Chemotherapy-induced nausea and vomiting (Prevention) in China (IV) before December 2025 (Jiangsu Hengrui Medicine pipeline, December 2025)
  • 16 Dec 2025 Fosrolapitant/palonosetron hydrocholoride - Fujian Shengdi Pharmaceutical receives Breakthrough Therapy status for Chemotherapy-induced nausea and vomiting in China before December 2025 ((Jiangsu Hengrui Medicine pipeline, December 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top